



13-15 October 2024 | Maison de la Mutualité, Paris

Rapid Re-Entry into HIV Care as a Low Barrier Model for Retention

Isolde Butler, MD, MPH



Disclosures

- I have no disclosures

CrescentCare
A Partnership for Life



1983: Agency founded

- Hotline, Counseling/Testing, Buddy Services

1990: Case Management Services

1991: Ryan White Funding

- Added Food Bank, Adherence Counseling

1999: Primary Medical Services

- Housing, Peer Support, Enhanced Outreach

2005: Hurricane Katrina

- Loss of infrastructure
- Engagement in Community Recover

2014: Federally Qualified Health Center

- Expand services to larger community





Becoming an FQHC



FEDERALLY QUALIFIED
HEALTH CENTER



HIGH QUALITY, EVIDENCE
BASED, COST EFFECTIVE
CARE FOR **ALL**



SLIDING FEE SCALE BASED
ON INCOME



AT LEAST 50% OF BOARD
ARE PATIENTS OF THE
HEALTH CENTER

Our Services

- Primary care
- PEP/PrEP services
- Gender affirming care
- Reproductive health
- Pediatrics
- Dentistry
- Behavioral Health
- Nutrition and health education
- Chronic disease management
- Sexual health and wellness




HIV Care & Support Services

2,800+ primary care patients living with HIV


- Legal services
- Food for Friends
- Housing Services
- Transportation
- Peer Support
- Case Management
- Emergency Financial Assistance

CrescentCare Start Initiative

In 2016, the CrescentCare Start Initiative (CCSI) was created with the purpose of providing individuals newly diagnosed with HIV with access to medical care within 72 hours of diagnosis, and access to antiretroviral treatment (ART) at their first provider visit.



CCSI Workflow



CCSI Successes

- December 2016 - December 2018: 291 individuals linked to care through CCSI
 - 97.3% linked to care within 30 days
 - 95% virally suppressed during measure period
 - Average of 28 days to viral suppression for all individuals

CCSI Success

Significant reduction in time to viral suppression

- Median time to viral suppression:
 - CCSI Group - 30 days
 - Historical Control – 68 days
- “Real World” environment
- Very high HIV prevalence
 - 1505/100,000 persons
 - 9th highest prevalence in US




FIG. 1.

The relationship between % virally suppressed (<200 copies/mL) and time to viral suppression among patients newly diagnosed with HIV infection as part of the CCSI compared to historical cohort. This Kaplan-Meier plot shows the proportion of patients with viral load <200 copies/mL HIV RNA over time. Time to viral suppression for patients in the CrescentCare Start Initiative was a median of 30 days (blue line) and significantly shorter than for patients treated in the historical cohort for 68 days (red line). CCSI, CrescentCare Start Initiative. (Color image can be found at www.liebertonline.com/apc).

Rapid Start Is Effective

- Multiple Studies Support
- Improved Time to Viral Suppression
- Durable viral retention over time
- Improved Retention in care
- Multiple clinical settings
- Various psychosocial conditions

Clinical Infectious Diseases

MAJOR ARTICLE

Decreased Time From Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation, and Virologic Suppression during the Citywide RAPID Initiative in San Francisco

Oliver Bacon,^{1,2*} Jennie Chin,³ Stephanie E. Cohen,¹ Nancy A. Hessel,⁴ Darpun Sachdev,^{1,2} Susa Coffey,³ Susan Scheer,³ Susan Buchbinder,¹ Diane V. Havlir,⁷ and Ling Hsu⁷



Labhardt et al. *BMC Public Health* (2016) 16:329
DOI 10.1186/s12889-016-2972-6

STUDY PROTOCOL

Same day ART initiation versus care as usual for individuals newly tested HIV-positive during community-based HIV testing in rural Lesotho – a randomized controlled trial (CASCADE trial)

Niklaus Daniel Labhardt,^{1,2*} Isaac Ringera,³ Thabo Ishmael Lejone,³ Phofu Masethothi,³ Tsepang Thaananyane,³ Mashaete Kamele,³ Ravi Shankar Gupta,⁴ Kyaw Thin,⁵ Bernard Cerutti,⁶ Thomas Klimkait,⁷ Christiane Fritz,⁷ and Tracy Renée Glass^{1,2,8}



HHS Public Access

Author manuscript

AIDS. Author manuscript; available in PMC 2020 February 19.

Published in final edited form as:

AIDS. 2019 April 01; 33(5): 825–832. doi:10.1097/QAD.0000000000002124.

RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population

Susa Coffey^a, Peter Bacchetti^b, Darpun Sachdev^c, Oliver Bacon^c, Diane Jones^c, Clarissa Ospina-Norvell^a, Sandra Torres^a, Elizabeth Lynch^a, Christy Camp^a, Remy Mercer-Slomoff^a, Sulggi Lee^a, Katerina Christopoulos^a, Christopher Pilcher^a, Ling Hsu^c, Chengshi Jin^b, Susan Scheer^c, Diane Havlir^a, Monica Gandhi^a

Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial

Sydney Rosen^{1,2*}, Mhairi Maskew², Matthew P. Fox^{2,3}, Cynthia Nyoni², Constance Mongwenyana², Given Malete², Ian Sanne², Dorah Bokaba⁴, Celeste Sauls², Julia Rohr¹, Lawrence Long²

1 Department of Global Health, Boston University School of Public Health, Boston, Massachusetts, United States of America, 2 Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, 3 Department of Epidemiology, Boston University School of Public Health, Boston, Massachusetts, United States of America, 4 Health Department, City of Johannesburg, Johannesburg, South Africa

Open Forum Infectious Diseases

MAJOR ARTICLE

Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States

Jonathan Colasanti,^{1,2,3,4} Jeri Sumitani,⁴ C. Christina Mehta,⁵ Yiran Zhang,⁵ Minh Ly Nguyen,^{1,2,4} Carlos del Rio,^{1,2,3,4} and Wendy S. Armstrong^{1,2,4}


RESEARCH ARTICLE

Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial

Serena P. Koenig^{1,2*}, Nancy Dorvil¹, Jessy G. Dévieux², Bethany L. Hedt-Gauthier⁴, Cynthia Riviere¹, Mikerlyne Faustin¹, Kerlyne Lavoie¹, Christian Perodin¹, Alexandra Anillon¹, Imathe Duverne¹, Marnaret I. McNair^{5,6}, Kally A. Hennecou¹



Continuum of Care: Louisiana 2016



Continuum of Care: Early vs. Late Initial Linkage




Figure 1. CCSI patients were linked within 72 hours of diagnosis. EIS patients were linked within 72 hours of contact to clinic. Retention in care criteria (2 visits separated by 3 months within the last 12 months) were significantly different between the two groups. Viral suppression last viral load <200 copies/ml and within the last six months were also significantly different between the two groups. Abbreviations: ART, antiretroviral therapy; CCSI, CrescentCare Start Initiative; EIS, Early Intervention Services.

Can Rapid Start Principles Apply to Reengagement?

- Rapid entry program in Atlanta included non-ARV naïve patients
 - 40% of cohort treatment experienced
 - New to clinic
- Success of low barrier models such as the Ward 86 program
- Community input
 - “What about the rest of us?”
 - Requests to engage those returning to care

- Matthew D Hickey, et al HIV Treatment Outcomes in POP-UP: Drop-in HIV Primary Care Model for People Experiencing Homelessness, *The Journal of Infectious Diseases*, Volume 226, Issue Supplement_3, 15 October 2022, Pages S353–S362, <https://doi.org/10.1093/infdis/jiac267>
- Colasanti J, et al. Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States. *Open Forum Infect Dis*. 2018 Jun 28;5(6):ofy104. doi: 10.1093/ofid/ofy104. PMID: 29992172; PMCID: PMC6022569.

Rapid Re-Entry (RRE) Program Overview



Purpose:

Cross department partnership to re-engage patients living with HIV in care



Eligibility:

Out of care for more than 9 months,
Returning to care,
In need of a medical visit / labs to maintain ART, **OR**
New to CrescentCare and out of ART.



Team:


Linkage Coordinators
RRE Providers & Care Teams
Eligibility Specialists
RRE Case Managers



Funding

Ryan White Part C (Orleans)
Ryan White Part C (Jefferson)
Ryan White Part A (New Orleans EMA)


Rapid Re-Entry Workflow




RRE – Demographics (March 2023 – Feb 2024)

269 completed an initial RRE visit


Patients by Race



Patients by Gender




Patients by Age Range




RRE Viral Suppression: Intake vs End of Reporting Period

Viral Suppression on Intake



Viral Suppression At End of Reporting Period (Total)




*70% of patients unsuppressed at the end of the reporting period only had one VL completed.




Outcomes: Unsuppressed on Initial Presentation

Initially Unsuppressed:
Viral Suppression at End of Reporting Period



Missing Labs on Intake:
Viral Suppression at End of Report Period




*Additional 11 patients achieved suppression after the reporting period




Genotypes: Unsuppressed at the End of the Reporting Period


Unsuppressed Patients with Genotype



Genotype Results



Initial ARV choice: Unsuppressed at End of Reporting Period



3 Regimens changed after initial visit among unsuppressed individuals

- Regimen simplified after genotype results
- Addition of DRV/c due to adherence concerns
- ELV/c/FTC/TAF → DRV/c/FTC/TAF due to INSTI resistance

RRE – Health Outcomes (March 2023 – Feb 2024)



Overall, 70% of all patients with RRE visits during the measure period were virally suppressed at the time of their most recent lab




55% of patients had upcoming appointments scheduled after the end of the 12-month measure period

Continuous Improvement




Staffing & Capacity



Workflows



Outreach



Repeat RREs

Conclusions and Limitations

- Re-engagement in care in complex
- Rapid re-initiation of ARV is acceptable to patients
- No significant emergence of resistance was noted in our cohort over the study period
- No control group
- Loss to follow up remains a major driver

Questions?